We are live on ! Find out more
CANF

Can-Fite BioPharma American Depositary Shares

6 hedge funds and large institutions have $1.3M invested in Can-Fite BioPharma American Depositary Shares in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% less ownership

Funds ownership: 0%0% (-0%)

14% less funds holding

Funds holding: 76 (-1)

29% less capital invested

Capital invested by funds: $1.84M → $1.3M (-$539K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.13%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
2
Reduced
1
Closed
1
Calls
Puts
Net Calls
Net Calls Change

CANF Hedge Fund Activity: Q1 2019 in Review

6 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q1 2019, worth a combined $1.3M — down 29% from $1.84M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CANF and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.

The largest buyer was Morgan Stanley, adding an estimated $217K. The largest seller was Taylor Asset Management, cutting an estimated $300K.

  • 6 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q1 2019, down from 7 in Q4 2018.
  • Funds reported $1.3M of Can-Fite BioPharma American Depositary Shares stock for Q1 2019, down 29% quarter-over-quarter.
  • 0 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q1 2019 and 1 closed out, a net change of -1 holder.
  • The largest Can-Fite BioPharma American Depositary Shares buyer in Q1 2019 was Morgan Stanley, an estimated $217K added.
  • The largest Can-Fite BioPharma American Depositary Shares seller in Q1 2019 was Taylor Asset Management, an estimated $300K sold.

Based on aggregated 13F filings for Q1 2019.